Cardiac allograft vasculopathy prevention
Cardiac allograft vasculopathy Microchapters |
Differentiating Cardiac allograft vasculopathy from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Cardiac allograft vasculopathy prevention On the Web |
American Roentgen Ray Society Images of Cardiac allograft vasculopathy prevention |
Directions to Hospitals Treating Cardiac allograft vasculopathy |
Risk calculators and risk factors for Cardiac allograft vasculopathy prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2] Raviteja Guddeti, M.B.B.S. [3]
Overview
Prevention
As the pathogenesis of CAV consists of both immunological and non-immunological insults, preventative strategies should consist of control of risk factors for CAV and optimal immunosuppressive therapy.
Optimization of Immunosuppressive Therapy
Options for immunosuppressive therapy for prevention of CAV include [1]:
- Calcineurin inhibitors, such as
- Sirolimus (Rapamycin)
- Everolimus, a Rapamycin derivative
- Corticosteroids
- Azathioprine
- Mycophenolate mofetil
Calcineurin inhibitors
References
- ↑ Mehra MR (2006). "Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy". Am J Transplant. 6 (6): 1248–56. doi:10.1111/j.1600-6143.2006.01314.x. PMID 16686747.